We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 14 juni 2018

The Lancet: [Media Watch] HIV criminalisation laws in the USA: built on phobias or facts?

[Media Watch] HIV criminalisation laws in the USA: built on phobias or facts?
Just when high income countries were starting to see the positive impact of the use of antibiotics to tackle infectious diseases, reports on AIDS in the 1980s as a infectious disease first appearing within gay communities posed a new public health challenge. Since then, AIDS has been proclaimed as a divine punishment for non-normative social behaviours such as drug abuse, prostitution, and gay sex. In the 1980s in the USA, some religious factions and politicians began terrifying people, demonising those behaviours rather than the virus as the cause for AIDS, and proclaiming that only coercion and punishment could curb it.
Read more

[Review] Experimental infection of human volunteers
Controlled human infection (CHI) trials, in which healthy volunteers are experimentally infected, can accelerate the development of novel drugs and vaccines for infectious diseases of global importance. The use of CHI models is expanding from around 60 studies in the 1970s to more than 120 publications in this decade, primarily for influenza, rhinovirus, and malaria. CHI trials have provided landmark data for several registered drugs and vaccines, and have generated unprecedented scientific insights.
Read more

[Corrections] Corrections
Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study. Lancet Infect Dis 2017; 17: 174–83—In this Article, the copyright line should have been "© 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license." This correction has been made to the online version as of June 12, 2018.
Read more

[Articles] Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
After a single dose of DSM265, P falciparum parasitaemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics. Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies.
Read more

[Comment] DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria
In The Lancet Infectious Diseases, Alejandro Llanos-Cuentas and colleagues1 report a pivotal phase 2a proof-of-concept study analysing different doses of the novel antimalarial compound DSM265 against uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Iquitos, Peru.
Read more